JP2021500345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500345A5 JP2021500345A5 JP2020521971A JP2020521971A JP2021500345A5 JP 2021500345 A5 JP2021500345 A5 JP 2021500345A5 JP 2020521971 A JP2020521971 A JP 2020521971A JP 2020521971 A JP2020521971 A JP 2020521971A JP 2021500345 A5 JP2021500345 A5 JP 2021500345A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrole
- hexahydro
- pyridazine
- cyclopentane
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C 1- C 4 alkoxy Chemical group 0.000 claims description 620
- QLSWIGRIBOSFMV-UHFFFAOYSA-N 1h-pyrrol-2-amine Chemical compound NC1=CC=CN1 QLSWIGRIBOSFMV-UHFFFAOYSA-N 0.000 claims description 237
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 212
- 150000003839 salts Chemical class 0.000 claims description 81
- 150000001875 compounds Chemical class 0.000 claims description 79
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 72
- 125000005843 halogen group Chemical group 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 28
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 26
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 23
- 125000001188 haloalkyl group Chemical group 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- RLOQBKJCOAXOLR-UHFFFAOYSA-N 1h-pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC=CN1 RLOQBKJCOAXOLR-UHFFFAOYSA-N 0.000 claims description 12
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims description 10
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000005916 2-methylpentyl group Chemical group 0.000 claims description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 6
- 208000016285 Movement disease Diseases 0.000 claims description 6
- 125000000732 arylene group Chemical group 0.000 claims description 6
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000005549 heteroarylene group Chemical group 0.000 claims description 6
- 208000014644 Brain disease Diseases 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 claims description 3
- DAIOMBQXJJLAGP-WHUJAJFLSA-N (3aR,6aS)-5-[[6-(1,3-dimethylpyrazol-4-yl)pyridazin-3-yl]oxymethyl]-2-(2-methylpentyl)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound CN1N=C(C(=C1)C1=CC=C(N=N1)OCC1C[C@@H]2[C@@H](CN(C2)CC(CCC)C)C1)C DAIOMBQXJJLAGP-WHUJAJFLSA-N 0.000 claims description 2
- VVSRMUFLDWLPAO-YQQQUEKLSA-N (3aR,6aS)-5-[[6-(2,4-dimethylpyrazol-3-yl)pyridazin-3-yl]oxymethyl]-2-(pyridin-2-ylmethyl)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound CN1N=CC(=C1C1=CC=C(N=N1)OCC1C[C@@H]2[C@@H](CN(C2)CC2=NC=CC=C2)C1)C VVSRMUFLDWLPAO-YQQQUEKLSA-N 0.000 claims description 2
- YKWOCPFTGFDRAE-IHWFROFDSA-N (3aR,6aS)-5-[[6-(2,4-dimethylpyrazol-3-yl)pyridazin-3-yl]oxymethyl]-2-[(3-methylpyridin-2-yl)methyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound CN1N=CC(=C1C1=CC=C(N=N1)OCC1C[C@@H]2[C@@H](CN(C2)CC2=NC=CC=C2C)C1)C YKWOCPFTGFDRAE-IHWFROFDSA-N 0.000 claims description 2
- KRGLJABYDQQAKG-OWCVQMPJSA-N (3aR,6aS)-5-[[6-(2-chloro-5-fluorophenyl)pyridazin-3-yl]oxymethyl]-2-(2-methylbutyl)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound ClC1=C(C=C(C=C1)F)C1=CC=C(N=N1)OCC1C[C@@H]2[C@@H](CN(C2)CC(CC)C)C1 KRGLJABYDQQAKG-OWCVQMPJSA-N 0.000 claims description 2
- IQCLDUKZKHIUJE-YQQQUEKLSA-N (3aS,6aR)-2-(1,3-benzodioxol-5-ylmethyl)-5-[[6-(2-chloro-5-fluorophenyl)pyridazin-3-yl]oxymethyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound O1COC2=C1C=CC(=C2)CN2C[C@@H]1[C@H](C2)CC(C1)COC=1N=NC(=CC1)C1=C(C=CC(=C1)F)Cl IQCLDUKZKHIUJE-YQQQUEKLSA-N 0.000 claims description 2
- JRBVCAZRMVVUEA-IUPNCAOTSA-N (3aS,6aR)-2-(1-adamantylmethyl)-5-[[6-(1,3-dimethylpyrazol-4-yl)pyridazin-3-yl]oxymethyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound C12(CC3CC(CC(C1)C3)C2)CN2C[C@@H]3[C@H](C2)CC(C3)COC=3N=NC(=CC3)C=3C(=NN(C3)C)C JRBVCAZRMVVUEA-IUPNCAOTSA-N 0.000 claims description 2
- GQWMIXXHURUTLX-IUPNCAOTSA-N (3aS,6aR)-2-(1-adamantylmethyl)-5-[[6-(2,4-dimethylpyrazol-3-yl)pyridazin-3-yl]oxymethyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound C12(CC3CC(CC(C1)C3)C2)CN2C[C@@H]3[C@H](C2)CC(C3)COC=3N=NC(=CC3)C=3N(N=CC3C)C GQWMIXXHURUTLX-IUPNCAOTSA-N 0.000 claims description 2
- UJQGCNPXKKRHAE-YQQQUEKLSA-N (3aS,6aR)-5-[[6-(1,3-dimethylpyrazol-4-yl)pyridazin-3-yl]oxymethyl]-2-(pyridin-2-ylmethyl)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound CN1N=C(C(=C1)C1=CC=C(N=N1)OCC1C[C@@H]2[C@@H](CN(C2)CC2=NC=CC=C2)C1)C UJQGCNPXKKRHAE-YQQQUEKLSA-N 0.000 claims description 2
- PUFWQVPXAXLXPK-IHWFROFDSA-N (3aS,6aR)-5-[[6-(1,3-dimethylpyrazol-4-yl)pyridazin-3-yl]oxymethyl]-2-[(3-methylpyridin-2-yl)methyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound CN1N=C(C(=C1)C1=CC=C(N=N1)OCC1C[C@@H]2[C@@H](CN(C2)CC2=NC=CC=C2C)C1)C PUFWQVPXAXLXPK-IHWFROFDSA-N 0.000 claims description 2
- SYUFWNRIRULXJE-WHUJAJFLSA-N (3aS,6aR)-5-[[6-(2,4-dimethylpyrazol-3-yl)pyridazin-3-yl]oxymethyl]-2-(2-methylpentyl)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound CN1N=CC(=C1C1=CC=C(N=N1)OCC1C[C@@H]2[C@@H](CN(C2)CC(CCC)C)C1)C SYUFWNRIRULXJE-WHUJAJFLSA-N 0.000 claims description 2
- QMERANYUOVTPRO-JLYLLQBASA-N (3aS,6aR)-5-[[6-(2-chloro-5-fluorophenyl)pyridazin-3-yl]oxymethyl]-2-[(2-fluorophenyl)methyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound ClC1=C(C=C(C=C1)F)C1=CC=C(N=N1)OCC1C[C@@H]2[C@@H](CN(C2)CC2=C(C=CC=C2)F)C1 QMERANYUOVTPRO-JLYLLQBASA-N 0.000 claims description 2
- YMHFAZSOMKSRGU-YQQQUEKLSA-N (3aS,6aR)-5-[[6-(2-chloro-5-fluorophenyl)pyridazin-3-yl]oxymethyl]-2-[(3-methylpyridin-2-yl)methyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound ClC1=C(C=C(C=C1)F)C1=CC=C(N=N1)OCC1C[C@@H]2[C@@H](CN(C2)CC2=NC=CC=C2C)C1 YMHFAZSOMKSRGU-YQQQUEKLSA-N 0.000 claims description 2
- RTNFURHJDNAKPS-YQQQUEKLSA-N (3aS,6aR)-5-[[6-(2-chloro-5-fluorophenyl)pyridazin-3-yl]oxymethyl]-2-[(4-fluorophenyl)methyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole Chemical compound ClC1=C(C=C(C=C1)F)C1=CC=C(N=N1)OCC1C[C@@H]2[C@@H](CN(C2)CC2=CC=C(C=C2)F)C1 RTNFURHJDNAKPS-YQQQUEKLSA-N 0.000 claims description 2
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000006622 cycloheptylmethyl group Chemical group 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 2
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 13
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 3
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical group [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 229910000870 Weathering steel Inorganic materials 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 4
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ZUWJIYXVNJOAQZ-UHFFFAOYSA-N 4-(2,4-dimethylpyrazol-3-yl)pyridazin-3-amine Chemical compound CN1N=CC(=C1C1=C(N=NC=C1)N)C ZUWJIYXVNJOAQZ-UHFFFAOYSA-N 0.000 description 1
- 0 CC*=C(N=*C(*(C)C)=S)SI Chemical compound CC*=C(N=*C(*(C)C)=S)SI 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574912P | 2017-10-20 | 2017-10-20 | |
| US62/574,912 | 2017-10-20 | ||
| PCT/US2018/056803 WO2019079783A1 (en) | 2017-10-20 | 2018-10-20 | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500345A JP2021500345A (ja) | 2021-01-07 |
| JP2021500345A5 true JP2021500345A5 (OSRAM) | 2021-12-02 |
| JP7270989B2 JP7270989B2 (ja) | 2023-05-11 |
Family
ID=66173904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521971A Active JP7270989B2 (ja) | 2017-10-20 | 2018-10-20 | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11299481B2 (OSRAM) |
| EP (1) | EP3697759A4 (OSRAM) |
| JP (1) | JP7270989B2 (OSRAM) |
| KR (2) | KR102776114B1 (OSRAM) |
| CN (2) | CN111491920B (OSRAM) |
| AU (2) | AU2018351651B2 (OSRAM) |
| CA (1) | CA3079617A1 (OSRAM) |
| IL (2) | IL273924B2 (OSRAM) |
| WO (1) | WO2019079783A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE057838T2 (hu) | 2016-06-07 | 2022-06-28 | Jacobio Pharmaceuticals Co Ltd | SHP2 inhibitorokként hasznos új heterociklusos származékok |
| TWI664175B (zh) | 2017-03-23 | 2019-07-01 | 大陸商北京加科思新藥研發有限公司 | 用於作為shp2抑制劑之新穎雜環衍生物 |
| WO2019058393A1 (en) | 2017-09-22 | 2019-03-28 | Jubilant Biosys Limited | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PAD |
| FI3697785T3 (fi) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidatsopyridiiniyhdisteitä pad:n estäjinä |
| JP7270989B2 (ja) * | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| JP2021503443A (ja) | 2017-10-31 | 2021-02-12 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| MX2020006587A (es) | 2017-12-22 | 2020-12-10 | Ravenna Pharmaceuticals Inc | Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. |
| AU2019216492A1 (en) * | 2018-02-02 | 2020-08-20 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| EP4037677B1 (en) * | 2019-10-04 | 2025-09-24 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP2023506741A (ja) * | 2019-12-10 | 2023-02-20 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| WO2021119254A1 (en) * | 2019-12-10 | 2021-06-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP2023515617A (ja) * | 2020-02-28 | 2023-04-13 | リミックス セラピューティクス インコーポレイテッド | 核酸スプライシングを調節するためのピリダジン誘導体 |
| WO2021216949A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| WO2021216951A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| ES2991955T3 (es) * | 2020-08-13 | 2024-12-05 | Univ Vanderbilt | Antagonistas del receptor muscarínico de la acetilcolina M4 |
| JP2023549534A (ja) * | 2020-11-18 | 2023-11-27 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| CA3206174A1 (en) * | 2020-12-22 | 2022-06-30 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CN116669737A (zh) * | 2020-12-22 | 2023-08-29 | 范德堡大学 | 毒蕈碱型乙酰胆碱受体m4的拮抗剂 |
| CN117120435A (zh) * | 2021-04-01 | 2023-11-24 | 小野药品工业株式会社 | Abhd6拮抗剂 |
| US20240174655A1 (en) * | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240228468A1 (en) * | 2021-04-05 | 2024-07-11 | Vanderbilt University | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders |
| WO2023016447A1 (en) * | 2021-08-09 | 2023-02-16 | Sironax Ltd. | Ferroptosis modulators, preparations, and uses thereof |
| WO2023141511A1 (en) * | 2022-01-19 | 2023-07-27 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726172A (en) * | 1996-01-16 | 1998-03-10 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| JP4703183B2 (ja) * | 2002-07-15 | 2011-06-15 | シンフォニー エボルーション， インク． | 受容体型キナーゼモジュレーターおよびその使用方法 |
| US20040044029A1 (en) | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
| DE60225195T2 (de) | 2002-12-23 | 2009-02-26 | Ranbaxy Laboratories, Ltd. | Flavaxat-derivate als muscarin-rezeptor antagonisten |
| US7517905B2 (en) | 2003-04-09 | 2009-04-14 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| ES2651730T3 (es) | 2003-09-26 | 2018-01-29 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2006035280A1 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases |
| WO2006035282A2 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| EP1904495A2 (en) | 2005-07-11 | 2008-04-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| WO2007138431A2 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| WO2008075172A2 (en) | 2006-12-19 | 2008-06-26 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CN101230058A (zh) * | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
| WO2011084796A2 (en) * | 2009-12-21 | 2011-07-14 | Qiang Zhang | Novel quinazoline derivatives |
| JP2012107001A (ja) * | 2010-10-22 | 2012-06-07 | Shionogi & Co Ltd | インドールアミド化合物を含有する医薬 |
| CN103102352B (zh) | 2011-11-15 | 2015-08-12 | 山东亨利医药科技有限责任公司 | 酪氨酸激酶抑制剂吲哚满酮衍生物 |
| AU2014244183A1 (en) | 2013-03-13 | 2015-08-13 | Abbvie Inc. | Pyridine CDK9 kinase inhibitors |
| EP3102198B1 (en) * | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| BR112016023117B1 (pt) | 2014-04-04 | 2023-02-07 | Pfizer Inc | Compostos de heteroarila ou arila bicíclicos fundidos |
| UA121658C2 (uk) | 2014-05-23 | 2020-07-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки 5-хлордифторметоксифенілпіразолопіримідину як інгібітори янус-кінази |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| MX386148B (es) | 2015-11-06 | 2025-03-18 | Neurocrine Biosciences Inc | Derivados de n-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para el tratamiento de enfermedades neurologicas. |
| MX385975B (es) * | 2016-02-16 | 2025-03-18 | Univ Vanderbilt | Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1. |
| US20170355708A1 (en) | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| EP3541373B1 (en) * | 2016-11-17 | 2023-11-01 | Merck Sharp & Dohme LLC | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| AU2018313802A1 (en) | 2017-08-08 | 2020-02-20 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| CA3079188A1 (en) | 2017-10-17 | 2019-04-25 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP7270989B2 (ja) * | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| JP2021503443A (ja) * | 2017-10-31 | 2021-02-12 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP2023506741A (ja) * | 2019-12-10 | 2023-02-20 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| WO2021119254A1 (en) * | 2019-12-10 | 2021-06-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2021216949A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| WO2021216951A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| CA3206174A1 (en) * | 2020-12-22 | 2022-06-30 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| US20240174655A1 (en) * | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240228468A1 (en) * | 2021-04-05 | 2024-07-11 | Vanderbilt University | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders |
| US20240287050A1 (en) * | 2021-06-11 | 2024-08-29 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
-
2018
- 2018-10-20 JP JP2020521971A patent/JP7270989B2/ja active Active
- 2018-10-20 AU AU2018351651A patent/AU2018351651B2/en active Active
- 2018-10-20 CN CN201880081828.0A patent/CN111491920B/zh active Active
- 2018-10-20 EP EP18869444.2A patent/EP3697759A4/en active Pending
- 2018-10-20 IL IL273924A patent/IL273924B2/en unknown
- 2018-10-20 KR KR1020207013966A patent/KR102776114B1/ko active Active
- 2018-10-20 KR KR1020257006587A patent/KR20250037575A/ko active Pending
- 2018-10-20 CA CA3079617A patent/CA3079617A1/en active Pending
- 2018-10-20 US US16/757,245 patent/US11299481B2/en active Active
- 2018-10-20 WO PCT/US2018/056803 patent/WO2019079783A1/en not_active Ceased
- 2018-10-20 CN CN202410064006.9A patent/CN118063442A/zh active Pending
- 2018-10-20 IL IL310346A patent/IL310346A/en unknown
-
2022
- 2022-03-07 US US17/688,709 patent/US11820757B2/en active Active
-
2023
- 2023-04-04 AU AU2023202086A patent/AU2023202086B2/en active Active
- 2023-10-13 US US18/486,712 patent/US20240116902A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500345A5 (OSRAM) | ||
| IL273924B1 (en) | Muscarinic acetylcholine M4 receptor antagonists | |
| JP2017530185A5 (OSRAM) | ||
| JP2010533158A5 (OSRAM) | ||
| JP2016523911A5 (OSRAM) | ||
| IL311187A (en) | Compressed ring compounds | |
| JP2014526549A5 (OSRAM) | ||
| JP2023113691A (ja) | Ｆｓｈｄの治療のためにｄｕｘ４および下流遺伝子発現を低減するｐ３８キナーゼ阻害剤 | |
| JP2019530695A5 (OSRAM) | ||
| HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| JP2009542638A5 (OSRAM) | ||
| JP2017528487A5 (OSRAM) | ||
| JP2008525502A5 (OSRAM) | ||
| JP2020526549A5 (OSRAM) | ||
| JP2012501312A5 (OSRAM) | ||
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| RU2018145045A (ru) | Соединения бензолсульфонамида и их применение в качестве терапевтических средств | |
| JP2019516737A5 (OSRAM) | ||
| JPWO2023064857A5 (OSRAM) | ||
| JP2017509676A5 (OSRAM) | ||
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| RU2020115915A (ru) | Бициклические сульфоны и сульфоксиды и способы их применения | |
| JP2013515040A5 (OSRAM) |